Andrew Phan, MD
Internal Medicine · Dallas, TXNPI 1467437863
Payments from drug & device makers
Across 11 payments — averaging $32.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$139
- Inari Medical, Inc.$60
- Stryker$60
- Abbott$39
- Curonix LLC$15
- Sanofi Pasteur Inc.$14
- plus $27 from 2 others
What the payments were for
- Consulting fees$144%
- Food & beverage$34096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 1 | $139 |
| Inari Medical, Inc. | 3 | $60 |
| Stryker | 1 | $60 |
| Abbott | 2 | $39 |
| Curonix LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$354 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $139,309 |
| JardianceEmpagliflozin | 23 | $39,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $28,370 |
| MounjaroTirzepatide | 25 | $28,290 |
| FarxigaDapagliflozin Propanediol | 29 | $26,670 |
| EliquisApixaban | 21 | $25,501 |
| XareltoRivaroxaban | 16 | $23,661 |
| MyrbetriqMirabegron | 17 | $9,797 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $8,857 |
| PaxlovidNirmatrelvir/Ritonavir | 32 | $5,716 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,920 |
| SynthroidLevothyroxine Sodium | 51 | $3,478 |
| Levothyroxine Sodium | 322 | $3,471 |
| Atorvastatin Calcium | 332 | $3,032 |
| Metoprolol Succinate | 180 | $2,562 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Dallas
- Amit VermaDallas$7.7M
- Valentine EbuhDallas$6.8M
- Gary SinclairDallas$3.4M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.